Mathieu Meunier

Dr. Mathieu Meunier


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MMMathieu Meunier
Mathieu Meunier
SASarah Ancelet
Sarah Ancelet
CLChristine Lefebvre
Christine Lefebvre
JAJosiane Arnaud
Josiane Arnaud
CGCatherine Garrel
Catherine Garrel
SPSophie Park
Sophie Park
Anemia is a frequent cytopenia in myelodysplastic syndromes (MDS) and most patients require red blood cell transfusion resulting in iron overload (IO). Deferasirox (DFX) has become the standard treatment of IO in MDS and it displays positive effects on erythropoiesis. In low risk MDS samples, mechanisms improving erythropoiesis after DFX treatment remain unclear. Herein, we addressed this question by using liquid cultures with iron overload of erythroid precursors treated with low dose of DFX (3μM), which corresponds to DFX 5 mg/kg/day, an unusual dose used for iron chelation. We highlight a decreased apoptosis rate and an increased proportion of cycling cells, both leading to higher proliferation rates. The iron chelation properties of low dose DFX failed to activate the Iron Regulatory Proteins and to support iron depletion, but low dose DFX dampers intracellular reactive oxygen species. Furthermore low concentrations of DFX activate the NF-κB pathway in erythroid precursors triggering anti-apoptotic and anti-inflammatory signals. Establishing stable gene silencing of the Thioredoxin (TRX) 1 genes, a NF-κB modulator, showed that fine-tuning of reactive oxygen species (ROS) levels regulates NF-κB. These results justify a clinical trial proposing low dose DFX in MDS patients refractory to erythropoiesis stimulating agents.

4 October 2018 in Haematologica
Verified
Journal Article
Open access
PDF file
Sophie ParkSophie Park
Sophie Park
OKOlivier Kosmider
Olivier Kosmider
FMFrédéric Maloisel
Frédéric Maloisel
BDBernard Drenou
Bernard Drenou
Nicolas ChapuisNicolas Chapuis
Nicolas Chapuis
MFMichaela Fontenay
Michaela Fontenay
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in lower risk myelodysplastic syndrome patients. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including flow cytometry RED score, serum GDF-15, and hepcidin levels. Inclusion criteria were: Erythropoiesis stimulating agents naive, IPSS low or intermediate-1 MDS with Hemoglobin level< 10g/dl, red blood cell transfusion-dependent or not. Patients received epoetin zeta 40 000 IU/week and erythroid response (IWG 2006 criteria) was assessed at week 12. Serum EPO level, iron parameters and hepcidin, flow cytometry Ogata and RED score, GDF-15, and molecular analysis by next-generation sequencing were determined at baseline. 70 patients were included. Median age was 78 years. There were 22 RCMD, 19 RCUD, 14 RARS, 4 RAEB-1, 6 CMML, 2 del 5q-, 3 unclassifiable, IPSS-R was 13 very low, 47 low, 9 intermediate and high. Twenty patients were transfusion dependent. Erythroid response was 48% and median response duration was 26 months. At baseline, non-responders had significantly higher RED score, lower hepcidin/ferritin ratio. In multivariate analysis, only RED score>4 (p=0.05) and hepcidin/ferritin2000 pg/ml and hepcidin/ferritin<9 (P=0.0008, and p=0.01, respectively). In multivariate analysis, both variables were associated with shorter response duration. Erythroid response to epoetin zeta was similar to that obtained with other erythropoiesis stimulating agents. It was correlated with higher baseline hepcidin/ferritin ratio and lower RED score.

1 March 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
SSSophie Servais
Sophie Servais
NDNicolas Dumontier
Nicolas Dumontier
LBLucie Biard
Lucie Biard
NSNathalie Schnepf
Nathalie Schnepf
MRMatthieu Resche-Rigon
Matthieu Resche-Rigon
MMMarie-Christine Mazeron
Marie-Christine Mazeron
Pre-emptive antiviral treatment efficiently prevents occurrence of cytomegalovirus (CMV) disease in allogeneic stem cell transplant recipients. However, successive treatment courses can be necessary. The current study was aimed at determining factors that could influence the response to antiviral treatment, in particular the donor CMV serostatus. A total of 147 consecutive CMV-seropositive recipients (R+) were included and prospectively monitored for 6 months after transplantation. Reactivation of CMV occurred in 111 patients, 61 of 78 with a CMV-positive donor (D+) and in 50 of 69 with a CMV-negative donor (D-) (p 0.45). Baseline viral loads and initial viral doubling times did not differ between D+/R+ and D-/R+. Fifteen D+/R+ and four D-/R+ had self-resolving CMV infections. A total of 92 patients received antiviral treatment and 81 (88%) had a significant decrease in CMV load under therapy. Repeated CMV episodes were observed in 67% of those and were significantly more frequent in D-/R+ than in D+/R+ (p <0001). Half-life of CMV under treatment was significantly longer in D-/R+ than in D+/R+. Treatment failure observed in eight recipients was associated with low leucocyte count at reactivation onset, and was significantly more frequent in D-/R+ (six patients) than in D+/R+ (two patients) (p <0.0001). CMV strains resistant to antivirals were found in two D-/R+. Donor CMV serostatus influenced neither CMV reactivation occurrence nor the kinetics of CMV DNA load in the early phase of CMV replication but had a significant impact on response to antiviral therapy. Virological drug-resistance remained rare.

12 February 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
MMMathieu Meunier
Mathieu Meunier
AGAudrey Guttin
Audrey Guttin
SASarah Ancelet
Sarah Ancelet
DLDavid Laurin
David Laurin
JZJohanna Zannoni
Johanna Zannoni
Sophie ParkSophie Park
Sophie Park

25 October 2019 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
Sophie ParkSophie Park
Sophie Park
CKCharikleia Kelaidi
Charikleia Kelaidi
MMMathieu Meunier
Mathieu Meunier
NCNicole Casadevall
Nicole Casadevall
AGAaron T. Gerds
Aaron T. Gerds
UPUwe Platzbecker
Uwe Platzbecker
Myelodysplastic syndromes (MDS) are hematopoietic stem cell malignancies associated with an erythroid maturation defect, resulting in anemia. Treatments for MDS include erythropoiesis-stimulating agents (ESAs). The identification of prognostic markers is important to help predict response and improve outcomes. Various scoring systems have been developed to help predict response to ESAs. Despite limitations in its assessment, serum erythropoietin (sEPO) level is an important predictor of hematologic response to ESAs in patients with lower-risk MDS. Numerous studies have reported significantly lower sEPO levels among responders versus non-responders. Furthermore, treatment response is significantly more likely among those with sEPO levels below versus those above various cutoffs. Other prognostic indicators for response to ESAs include lower transfusion requirement, fewer bone marrow blasts, higher hemoglobin, lower serum ferritin, lower-risk MDS, and more normal cytogenetics. Studies of other MDS therapies (e.g., lenalidomide and luspatercept) have also reported that lower sEPO levels are indicative of hematologic response. In addition, lower sEPO levels (up to 500 IU/L) have been included in treatment algorithms for patients with lower-risk MDS to define whether ESAs are indicated. Lower sEPO levels are predictive of hematologic response—particularly to ESAs. Further, clinical trials should use sEPO thresholds to ensure more homogeneous cohorts.

1 January 2020 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JBJulie Brault
Julie Brault
BVBénédicte Vigne
Bénédicte Vigne
MMMathieu Meunier
Mathieu Meunier
SBSylvain Beaumel
Sylvain Beaumel
MMMichelle Mollin
Michelle Mollin
MSMarie Jose STASIA
Marie Jose STASIA